You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to August 2024

AbstractFullPdf
Jun 20171200
Jul 20177401
Aug 20172202
Sep 20173804
Oct 20173806
Nov 20174601
Dec 20171201
Jan 20182204
Feb 20184405
Mar 20181602
Apr 201840014
May 20181802
Jun 20183001
Jul 20182000
Aug 20184200
Sep 20181404
Oct 2018203
Nov 20181002
Dec 20181403
Jan 2019601
Feb 2019601
Mar 2019804
Apr 20192405
May 2019804
Jun 2019402
Jul 2019605
Aug 2019202
Sep 2019602
Oct 2019801
Nov 2019602
Dec 2019400
Jan 20201202
Feb 2020402
Mar 2020602
Apr 20201003
May 2020002
Jun 20201002
Jul 20201204
Aug 2020604
Sep 20201402
Oct 2020605
Nov 2020801
Dec 2020403
Jan 2021402
Feb 2021402
Mar 2021403
Apr 20212002
May 2021200
Jun 2021002
Jul 2021005
Aug 2021003
Sep 2021103
Oct 20218017
Nov 2021508
Dec 20211202
Jan 2022501
Feb 2022200
Mar 20221105
Apr 20221806
May 2022806
Jun 20222603
Jul 20221101
Aug 20221002
Sep 2022706
Oct 20221007
Nov 2022405
Dec 2022800
Jan 2023603
Feb 2023401
Mar 20231000
Apr 2023803
May 2023003
Jun 2023801
Jul 2023202
Aug 2023402
Sep 2023001
Oct 2023200
Nov 2023403
Dec 2023801
Jan 2024201
Feb 2024202
Mar 20248076
Apr 202418025
May 2024602
Jun 2024500
Jul 2024403
Aug 2024801
Total9830337